vs
Reddit, Inc.（RDDT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Reddit, Inc.的季度营收约是Royalty Pharma plc的1.2倍（$725.6M vs $622.0M），Reddit, Inc.净利率更高（34.7% vs 34.4%，领先0.2%），Reddit, Inc.同比增速更快（69.7% vs 4.8%），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 4.6%）
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
RDDT vs RPRX — 直观对比
营收规模更大
RDDT
是对方的1.2倍
$622.0M
营收增速更快
RDDT
高出64.9%
4.8%
净利率更高
RDDT
高出0.2%
34.4%
两年增速更快
RDDT
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $725.6M | $622.0M |
| 净利润 | $251.6M | $214.2M |
| 毛利率 | 91.9% | — |
| 营业利润率 | 31.9% | 62.4% |
| 净利率 | 34.7% | 34.4% |
| 营收同比 | 69.7% | 4.8% |
| 净利润同比 | 254.2% | 2.9% |
| 每股收益（稀释后） | $1.24 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDDTRPRX
| Q4 25 | $725.6M | $622.0M | ||
| Q3 25 | $584.9M | $609.3M | ||
| Q2 25 | $499.6M | $578.7M | ||
| Q1 25 | $392.4M | $568.2M | ||
| Q4 24 | $427.7M | $593.6M | ||
| Q3 24 | $348.4M | $564.7M | ||
| Q2 24 | $281.2M | $537.3M | ||
| Q1 24 | $243.0M | $568.0M |
净利润RDDTRPRX
| Q4 25 | $251.6M | $214.2M | ||
| Q3 25 | $162.7M | $288.2M | ||
| Q2 25 | $89.3M | $30.2M | ||
| Q1 25 | $26.2M | $238.3M | ||
| Q4 24 | $71.0M | $208.2M | ||
| Q3 24 | $29.9M | $544.0M | ||
| Q2 24 | $-10.1M | $102.0M | ||
| Q1 24 | $-575.1M | $4.8M |
毛利率RDDTRPRX
| Q4 25 | 91.9% | — | ||
| Q3 25 | 91.0% | — | ||
| Q2 25 | 90.8% | — | ||
| Q1 25 | 90.5% | — | ||
| Q4 24 | 92.6% | — | ||
| Q3 24 | 90.1% | — | ||
| Q2 24 | 89.5% | — | ||
| Q1 24 | 88.6% | — |
营业利润率RDDTRPRX
| Q4 25 | 31.9% | 62.4% | ||
| Q3 25 | 23.7% | 70.1% | ||
| Q2 25 | 13.6% | 36.3% | ||
| Q1 25 | 1.0% | 94.0% | ||
| Q4 24 | 12.4% | 60.9% | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | -11.0% | 50.2% | ||
| Q1 24 | -242.5% | -13.0% |
净利率RDDTRPRX
| Q4 25 | 34.7% | 34.4% | ||
| Q3 25 | 27.8% | 47.3% | ||
| Q2 25 | 17.9% | 5.2% | ||
| Q1 25 | 6.7% | 41.9% | ||
| Q4 24 | 16.6% | 35.1% | ||
| Q3 24 | 8.6% | 96.3% | ||
| Q2 24 | -3.6% | 19.0% | ||
| Q1 24 | -236.7% | 0.8% |
每股收益（稀释后）RDDTRPRX
| Q4 25 | $1.24 | $0.49 | ||
| Q3 25 | $0.80 | $0.67 | ||
| Q2 25 | $0.45 | $0.07 | ||
| Q1 25 | $0.13 | $0.55 | ||
| Q4 24 | $4.76 | $0.46 | ||
| Q3 24 | $0.16 | $1.21 | ||
| Q2 24 | $-0.06 | $0.23 | ||
| Q1 24 | $-8.19 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $953.6M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.9B | $9.7B |
| 总资产 | $3.2B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资RDDTRPRX
| Q4 25 | $953.6M | $618.7M | ||
| Q3 25 | $911.7M | $938.9M | ||
| Q2 25 | $734.1M | $631.9M | ||
| Q1 25 | $635.7M | $1.1B | ||
| Q4 24 | $562.1M | $929.0M | ||
| Q3 24 | $515.9M | $950.1M | ||
| Q2 24 | $468.0M | $1.8B | ||
| Q1 24 | $968.5M | $843.0M |
总债务RDDTRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益RDDTRPRX
| Q4 25 | $2.9B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.4B | $9.5B | ||
| Q1 25 | $2.2B | $9.8B | ||
| Q4 24 | $2.1B | $10.3B | ||
| Q3 24 | $2.0B | $10.3B | ||
| Q2 24 | $1.9B | $9.8B | ||
| Q1 24 | $1.8B | $9.9B |
总资产RDDTRPRX
| Q4 25 | $3.2B | $19.6B | ||
| Q3 25 | $2.9B | $19.3B | ||
| Q2 25 | $2.6B | $18.3B | ||
| Q1 25 | $2.4B | $17.6B | ||
| Q4 24 | $2.3B | $18.2B | ||
| Q3 24 | $2.2B | $18.0B | ||
| Q2 24 | $2.1B | $17.7B | ||
| Q1 24 | $2.0B | $16.1B |
负债/权益比RDDTRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $266.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $263.6M | — |
| 自由现金流率自由现金流/营收 | 36.3% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | 1.06× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $684.2M | — |
8季度趋势，按日历期对齐
经营现金流RDDTRPRX
| Q4 25 | $266.8M | $827.1M | ||
| Q3 25 | $185.2M | $702.6M | ||
| Q2 25 | $111.3M | $364.0M | ||
| Q1 25 | $127.6M | $596.1M | ||
| Q4 24 | $90.0M | $742.5M | ||
| Q3 24 | $71.6M | $703.6M | ||
| Q2 24 | $28.4M | $658.2M | ||
| Q1 24 | $32.1M | $664.6M |
自由现金流RDDTRPRX
| Q4 25 | $263.6M | — | ||
| Q3 25 | $183.1M | — | ||
| Q2 25 | $110.8M | — | ||
| Q1 25 | $126.6M | — | ||
| Q4 24 | $89.2M | — | ||
| Q3 24 | $70.3M | — | ||
| Q2 24 | $27.2M | — | ||
| Q1 24 | $29.2M | — |
自由现金流率RDDTRPRX
| Q4 25 | 36.3% | — | ||
| Q3 25 | 31.3% | — | ||
| Q2 25 | 22.2% | — | ||
| Q1 25 | 32.3% | — | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 9.7% | — | ||
| Q1 24 | 12.0% | — |
资本支出强度RDDTRPRX
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.2% | — |
现金转化率RDDTRPRX
| Q4 25 | 1.06× | 3.86× | ||
| Q3 25 | 1.14× | 2.44× | ||
| Q2 25 | 1.25× | 12.06× | ||
| Q1 25 | 4.88× | 2.50× | ||
| Q4 24 | 1.27× | 3.57× | ||
| Q3 24 | 2.40× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
